NOTE: This order is nonprecedential.

United States Court of Appeals for the Federal Circuit

June 16, 2023

ERRATA

Appeal No. 21-1924

UCB, INC., UCB PHARMA GMBH, LTS LOHMANN THERAPIE-SYSTEME AG,

Plaintiffs-Appellants

 \mathbf{v} .

ACTAVIS LABORATORIES UT, INC.,

Defendant-Appellee

Appeal No. 21-2336

UCB, INC., UCB PHARMA GMBH, LTS LOHMANN THERAPIE-SYSTEME AG,

 $Plaintiffs\hbox{-} Appellants$

v.

MYLAN TECHNOLOGIES INC.,

Defendant-Appellee

Decided: April 12, 2023 Precedential Opinion

i recedentiai Opinion

2 UCB, INC. v. ACTAVIS LABORATORIES UT, INC.

Please make the following change to the caption in the opinion and judgment issued April 12, 2023, and the order granting an extension of time issued May 8, 2023:¹

UCB, INC., UCB PHARMA GMBH, LTS LOHMANN THERAPIE-SYSTEME AG,

Plaintiffs-Appellants

v.

ACTAVIS LABORATORIES UT, INC.,

Defendant-Appellee

2021-1924

Appeal from the United States District Court for the District of Delaware in No. 1:19-cv-00474-KAJ, Circuit Judge Kent A. Jordan.

UCB, INC., UCB PHARMA GMBH, LTS LOHMANN THERAPIE-SYSTEME AG,

 $Plaintiffs ext{-}Appellants$

 \mathbf{v} .

MYLAN TECHNOLOGIES INC.,

Defendant-Appellee

2021-2336

Appeal from the United States District Court for the District of Vermont in No. 2:19-cv-00128-cr, Judge Christina Reiss.

¹ The originating tribunal information has been corrected to state that Appeal No. 2021-2336 originated from the United States District Court for the District of Vermont.